

Date: 15 June 2024

To  
The Manager  
Department of Corporate Services  
BSE Limited  
25th Floor, P. J. Towers,  
Dalal Street, Mumbai - 400 001

To  
The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

**Sub: Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

**Ref: Scheme of amalgamation of Casper Pharma Private Limited (a wholly owned subsidiary of Suven Pharmaceuticals Limited) into and with Suven Pharmaceuticals Limited under Sections 230 and 232 of the Companies Act, 2013 and other applicable rules and/or regulations.**

Dear Sir/Madam,

This is in continuation to our communication dated 29 February 2024, wherein we had informed the stock exchanges that the board of directors of Suven Pharmaceuticals Limited (“**Company**”/“**Transferee Company**”) has approved the scheme of amalgamation of Casper Pharma Private Limited (“**Transferor Company**”) (a wholly owned subsidiary of the Company) into and with the Company under the provisions of Sections 230 to 232 of the Companies Act, 2013 subject to receipt of applicable approvals including jurisdictional NCLT (“**Scheme of Amalgamation**”).

In the above context, we are pleased to inform that Hon’ble NCLT, Mumbai Bench has passed an order dated 14 June 2024 (as uploaded on the official website of the NCLT (<https://nclt.gov.in/>) dispensing with the meetings of equity shareholders, secured creditors and unsecured creditors of both the Transferor Company and the Transferee Company and directed, *inter-alia* the Transferor Company and the Transferee Company to serve notices through registered post on the concerned regulatory authorities for their objections, if any, to the sanctioning of the Scheme of Amalgamation.

We request you to take this disclosure on your records.

Thanking you,  
Yours faithfully,  
For **Suven Pharmaceuticals Limited**

**K. Hanumantha Rao**  
Company Secretary

## Suven Pharmaceuticals Limited

**Registered Office:** # 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala Midc, Mumbai- 400093, Maharashtra, India  
Tel: 91 22 61539999

**Corporate Office:** # 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIIIC, Raidurg, Hyderabad - 500081 Telangana, India  
Tel: 91 40 2354 9414 / 3311

Email: [info@suvenpharm.com](mailto:info@suvenpharm.com) | Website: [www.suvenpharm.com](http://www.suvenpharm.com) | CIN: L24299MH2018PLC422236